{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:11:38Z","timestamp":1793232698776,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.04.027","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T09:27:40Z","timestamp":1587029260000},"page":"4170-4182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Archetype analysis of older adult immunization decision-making and implementation in 34 countries"],"prefix":"10.1016","volume":"38","author":[{"given":"Lois","family":"Privor-Dumm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prarthana","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10033","key":"10.1016\/j.vaccine.2020.04.027_b0005","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","article-title":"The World report on ageing and health: a policy framework for healthy ageing","volume":"387","author":"Beard","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.04.027_b0010","doi-asserted-by":"crossref","unstructured":"GBD 2017 DALY and Hale Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1859\u20131922.","DOI":"10.1016\/S0140-6736(18)32335-3"},{"issue":"4","key":"10.1016\/j.vaccine.2020.04.027_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"key":"10.1016\/j.vaccine.2020.04.027_b0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fimmu.2016.00041","article-title":"T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines","volume":"7","author":"McElhaney","year":"2016","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.04.027_b0025","first-page":"109","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vacc"},{"issue":"2","key":"10.1016\/j.vaccine.2020.04.027_b0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: A systematic review","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2020.04.027_b0035","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1377\/hlthaff.2016.0462","article-title":"Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"14","key":"10.1016\/j.vaccine.2020.04.027_b0040","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.vaccine.2019.01.002","article-title":"Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50\u201364years compared to the US general population","volume":"37","author":"Wateska","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","article-title":"Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia","volume":"17","author":"Friesen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.04.027_b0050","doi-asserted-by":"crossref","first-page":"105734","DOI":"10.1016\/j.ypmed.2019.05.022","article-title":"A review of the cost-effectiveness of adult influenza vaccination and other preventive services","volume":"126","author":"Dabestani","year":"2019","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2020.04.027_b0055","unstructured":"United Nations Department of Economic and Social Affairs Population Division. World Population Prospects 2019: Highlights; 2019."},{"key":"10.1016\/j.vaccine.2020.04.027_b0060","unstructured":"European Commission. In Sobczak D, editor. Population ageing in Europe. Facts, implications and policies. Brussels: European Commission Directorate\u2010General for Research and Innovation Socioeconomic sciences and humanities; 2014."},{"issue":"2","key":"10.1016\/j.vaccine.2020.04.027_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/07853890.2019.1588470","article-title":"Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion","volume":"51","author":"Doherty","year":"2019","journal-title":"Ann Med"},{"key":"10.1016\/j.vaccine.2020.04.027_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12979-017-0107-2","article-title":"Vaccines for the elderly: current use and future challenges","volume":"15","author":"Weinberger","year":"2018","journal-title":"Immun Ageing"},{"issue":"19","key":"10.1016\/j.vaccine.2020.04.027_b0075","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.vaccine.2018.03.053","article-title":"The public health value of vaccination for seniors in Europe","volume":"36","author":"Esposito","year":"2018","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.04.027_b0080","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: Needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40266-018-0597-4","article-title":"Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications","volume":"36","author":"Andrew","year":"2019","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chest.2018.10.044","article-title":"Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD","volume":"155","author":"Mulpuru","year":"2019","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.vaccine.2020.04.027_b0095","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.vaccine.2017.12.029","article-title":"Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22\u201323 March 2017","volume":"36","author":"Teresa Aguado","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2020.04.027_b0100","doi-asserted-by":"crossref","first-page":"e0186903","DOI":"10.1371\/journal.pone.0186903","article-title":"The full benefits of adult pneumococcal vaccination: A systematic review","volume":"12","author":"Cafiero-Fonseca","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2020.04.027_b0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3810\/pgm.2012.05.2550","article-title":"Identifying barriers to adult pneumococcal vaccination: an NFID task force meeting","volume":"124","author":"Rehm","year":"2012","journal-title":"Postgrad Med"},{"issue":"9","key":"10.1016\/j.vaccine.2020.04.027_b0110","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4161\/21645515.2014.982998","article-title":"Adult vaccination: Now is the time to realize an unfulfilled potential","volume":"11","author":"Tan","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.04.027_b0115","doi-asserted-by":"crossref","unstructured":"National Vaccine Advisory C. A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011. Public Health Rep 2012;127(Suppl 1):1\u201342.","DOI":"10.1177\/00333549121270S101"},{"issue":"36","key":"10.1016\/j.vaccine.2020.04.027_b0120","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1016\/j.vaccine.2017.07.100","article-title":"Focusing on the implementation of 21st century vaccines for adults","volume":"36","author":"Bonanni","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.04.027_b0125","first-page":"1777","article-title":"Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)","volume":"12","author":"Esposito","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.04.027_b0130","first-page":"5","article-title":"First Mexican Consensus of Vaccination in Adults","volume":"153","author":"Gutierrez-Robledo","year":"2017","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.vaccine.2020.04.027_b0135","unstructured":"SAATI Partnership. Supporting Active Ageing Through Immunisation Partnership. Adult vaccination: a key component of healthy ageing \u2013 The benefits of life-course immunisation in Europe; 2013."},{"issue":"45","key":"10.1016\/j.vaccine.2020.04.027_b0140","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: Analysis of the 2014 WHO\/UNICEF Joint Reporting Form on immunization","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.027_b0145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00038-012-0438-x","article-title":"Adult immunization policies in advanced economies: vaccination recommendations, financing, and vaccination coverage","volume":"58","author":"Wu","year":"2013","journal-title":"Int J Public Health"},{"issue":"35","key":"10.1016\/j.vaccine.2020.04.027_b0150","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1016\/j.vaccine.2012.06.012","article-title":"Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage","volume":"30","author":"Kanitz","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.04.027_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/07853890.2017.1417632","article-title":"Challenges in adult vaccination","volume":"50","author":"de Gomensoro","year":"2018","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.027_b0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5694\/mja16.00811","article-title":"Vaccine myopia: adult vaccination also needs attention","volume":"206","author":"Menzies","year":"2017","journal-title":"Med J Aust"},{"issue":"6","key":"10.1016\/j.vaccine.2020.04.027_b0165","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/1753-6405.12944","article-title":"What isn't measured isn't done - eight years with no progress in Aboriginal and Torres Strait Islander adult influenza and pneumococcal vaccination","volume":"43","author":"Webster","year":"2019","journal-title":"Aust N Z J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0170","first-page":"15","article-title":"A Blueprint for Improving the Promotion and Delivery of Adult Vaccination in the United States","volume":"2","author":"Harris","year":"2012","journal-title":"Rand Health Q"},{"key":"10.1016\/j.vaccine.2020.04.027_b0175","unstructured":"The World Health Organization. The Global Vaccine Action Plan 2011\u20132020. Geneva; 2013."},{"key":"10.1016\/j.vaccine.2020.04.027_b0180","unstructured":"The World Health Organization. Immunization Agenda 2030: A Global Strategy To Leave No One Behind. 2019 January 6, 2020]; SAGE Submission. Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/2_ia2030_SAGE_submission.pdf?ua=1."},{"issue":"32","key":"10.1016\/j.vaccine.2020.04.027_b0185","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.vaccine.2014.05.026","article-title":"Evidence-to-policy gap on hepatitis A vaccine adoption in 6 countries: Literature vs. policymakers' beliefs","volume":"32","author":"Ozawa","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.027_b0190","doi-asserted-by":"crossref","unstructured":"Sauer M, V.P., Meghani A, Luthra A, Garcia C, Knoll M, Privor-Dumm L, Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries 2020 [in press].","DOI":"10.1016\/j.vaccine.2021.01.066"},{"key":"10.1016\/j.vaccine.2020.04.027_b0195","first-page":"123","article-title":"An activity report of physicians of the Department of General Medicine, Juntendo University School of Medicine against the Great East Japan Earthquake","volume":"38","author":"Naito","year":"2015","journal-title":"J Gen Family Med"},{"issue":"7","key":"10.1016\/j.vaccine.2020.04.027_b0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jiac.2014.03.004","article-title":"Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake","volume":"20","author":"Naito","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2020.04.027_b0205","unstructured":"Ministy of Health, Labour, and Welfare. Pneumococcal vaccine (PPSV23); 2018."},{"key":"10.1016\/j.vaccine.2020.04.027_b0210","unstructured":"Superior Health Council Belgium. Advies 9141 \u2013 Basisvaccinatieschema; 2019; Available from: https:\/\/www.health.belgium.be\/en\/node\/35437#anchor-35437."},{"issue":"3","key":"10.1016\/j.vaccine.2020.04.027_b0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.healthpol.2013.09.007","article-title":"Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems","volume":"113","author":"Allen","year":"2013","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.vaccine.2020.04.027_b0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1370\/afm.697","article-title":"Different paths to high-quality care: three archetypes of top-performing practice sites","volume":"5","author":"Feifer","year":"2007","journal-title":"Ann Fam Med"},{"issue":"7","key":"10.1016\/j.vaccine.2020.04.027_b0225","first-page":"A832","article-title":"Segmentation of Seven Asia-Pacific Health Technology Assessment (HTA) Agencies into Different Evolutionary HTA Archetypes","volume":"19","author":"Mazumder","year":"2016","journal-title":"Value Health"},{"issue":"46","key":"10.1016\/j.vaccine.2020.04.027_b0235","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1016\/j.vaccine.2016.09.020","article-title":"Integrating pharmacies into public health program planning for pandemic influenza vaccine response","volume":"34","author":"Fitzgerald","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.04.027_b0240","unstructured":"CDC. Deaths Related to 2009 Pandemic Influenza A (H1N1) Among American Indian\/Alaska Natives - 12 states; 2009."},{"key":"10.1016\/j.vaccine.2020.04.027_b0245","unstructured":"CDC. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP); 2010."},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0250","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12889-018-5284-1","article-title":"The public health emergency management system in China: trends from 2002 to 2012","volume":"18","author":"Sun","year":"2018","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.vaccine.2020.04.027_b0255","doi-asserted-by":"crossref","first-page":"307","DOI":"10.15585\/mmwr.mm6911e1","article-title":"Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020","volume":"69","author":"Ng","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.04.027_b0265","unstructured":"Johns Hopkins University and Medicine. Coronavirus Resource Center; 2020 [cited 2020 April 5]; Available from: https:\/\/coronavirus.jhu.edu\/map.html."},{"issue":"4","key":"10.1016\/j.vaccine.2020.04.027_b0270","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2471\/BLT.13.125989","article-title":"Early response to the emergence of influenza A(H7N9) virus in humans in China: the central role of prompt information sharing and public communication","volume":"92","author":"Vong","year":"2014","journal-title":"Bull World Health Organ"},{"issue":"10226","key":"10.1016\/j.vaccine.2020.04.027_b0275","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(20)30522-5","article-title":"COVID-19: too little, too late?","volume":"395","author":"Lancet","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2020.04.027_b0280","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1186\/s12889-019-8044-y","article-title":"Pharmacy-based interventions to increase vaccine uptake: report of a multidisciplinary stakeholders meeting","volume":"19","author":"Ecarnot","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2020.04.027_b0285","unstructured":"Privor-Dumm L. Life-course immunization: Building the consensus for adult vaccination in IFPMA Thought Leader Series; 2019."},{"issue":"9595","key":"10.1016\/j.vaccine.2020.04.027_b0290","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(07)61579-7","article-title":"Generation of political priority for global health initiatives: a framework and case study of maternal mortality","volume":"370","author":"Shiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.04.027_b0295","unstructured":"Cull A. Characterizing Global Vaccine Hesitancy: How Adult and Pediatric Hesitancy May Differ. Johns Hopkins Bloomberg School of Public Health; 2019."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20305077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:20Z","timestamp":1759401800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20305077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":57,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20305077"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Archetype analysis of older adult immunization decision-making and implementation in 34 countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}